Showing results (591-600 of 3,470) with videos related to
Sort By:
Pageof 347
Clinical Pharmacokinetics|April 28, 2006
An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysisDesmond Padhi, Liyun Ni, Blaire Cooke, et al.Clinical Pharmacokinetics|August 25, 2006
Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patientsFranck Saint-Marcoux, Pierre Marquet, Evelyne Jacqz-Aigrain, et al.Clinical Pharmacokinetics|August 25, 2006
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and childrenTrevor N Johnson, Amin Rostami-Hodjegan, Geoffrey T TuckerClinical Pharmacokinetics|June 10, 2010
Rate and extent of drug accumulation after multiple dosing revisitedDion R Brocks, Reza MehvarClinical Pharmacokinetics|June 10, 2010
Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factorIftekhar MahmoodClinical Pharmacokinetics|July 9, 2010
Drug-drug interaction profiles of proton pump inhibitorsRyuichi Ogawa, Hirotoshi EchizenClinical Pharmacokinetics|August 10, 2010
Risk assessment in extrapolation of pharmacokinetics from preclinical data to humansZvi Teitelbaum, Thierry Lave, Jan Freijer, et al.Clinical Pharmacokinetics|September 8, 2010
Development of a population pharmacokinetic model for atorvastatin acid and its lactone metaboliteRajesh Narwal, Fatemeh Akhlaghi, Anders Asberg, et al.Clinical Pharmacokinetics|September 15, 2007
Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patientsJuan Jose Perez-Ruixo, Peter Zannikos, Sarapee Hirankarn, et al.Clinical Pharmacokinetics|December 1, 1991
Pharmacokinetic interactions with calcium channel antagonists (Part II)K D Schlanz, S A Myre, M B BottorffPageof 347